Compare Chevron Corp (CVX) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Chevron Corp vs Cassava Sciences Inc — how do they compare? Chevron Corp trades at $179.64 (market cap $361.99B), while Cassava Sciences Inc trades at $1.1 (market cap $52.66M). The key difference: Chevron Corp is far larger — about 6874.1× Cassava Sciences Inc's market cap, and Chevron Corp pays a 3.92% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| CVX | FLNA | |
|---|---|---|
Market Cap | $361.99B | $52.66M |
Volume | 9,807,834 | — |
Sector | Energy | Health |
52-Week High | $211.14 | $4.64 |
52-Week Low | $146.72 | $1.09 |
Enterprise Value | $402.09B | -$33.92M |
Dividend Yield | 3.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVX trades at $182.21, up 3.29% on the day, with bullish technical signals from moving averages and ADX indicators. Recent earnings have consistently beaten expectations, with Q1 2026 EPS of $1.41 surpassing the $1.00 estimate. The company maintains strong operating cash flow of $33.94 billion in 2025 and announced a $13.8 billion investment in Argentina's Vaca Muerta shale project, signaling growth commitment.
The outlook remains positive with a consensus price target of $207.56, implying 13.9% upside. High oil prices and strategic expansions support growth, but declining profit margins and geopolitical tensions pose risks. Analyst sentiment is strongly bullish with 62% buy ratings, though investors should monitor debt levels, which rose to 12.35% of assets in 2025.
FLNA trades at $1.15, down 2.54% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company continues to report losses, with a net income of -$90.97M in 2025 and negative cash flow, though it has beaten EPS estimates for the last three quarters. Recent news highlights ongoing development in its TSC-related epilepsy therapies.
Despite consistent earnings beats, FLNA's negative profitability and cash burn pose significant risks. Analyst sentiment is positive with a 66.7% buy rating, but the stock's outlook depends heavily on clinical success and future funding. Investors should weigh the high-risk, high-reward nature of this biotech play.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Chevron Corp
Chevron Corporation is an integrated energy company with operations in countries located around the world. The Company produces and transports crude oil and natural gas. Chevron also refines, markets, and distributes fuels, as well as is involved in chemical and mining operations, power generation, and energy services.
Read more on CVX →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
